laine Haynes is President and CEO of KaloCyte, Inc., a pre-clinical biotech startup developing an artificial red blood cell substitute that can be freeze-dried and stored for use when blood is not available. She has raised over $4M in investor funding and $11M in non-dilutive grant funding for KaloCyte, moved the company to Baltimore and grew the team to 10 employees. She is a seasoned business leader with over 35 years of healthcare experience and extensive expertise with development and commercialization of complex pharmaceuticals including radiopharmaceuticals, medical devices, sterile products, and controlled substances. Previously a VP/GM at Mallinckrodt Pharmaceuticals, her expertise includes championing new product and commercial development programs, product launches, lifecycle management, general management, oversight of and collaboration with manufacturing, quality and regulatory affairs, capital equipment and plant expansion projects, P&L and budget management, and FDA interactions including new approvals, product recalls, safety monitoring and post-marketing reporting, M&A and divestitures. She completed her executive MBA at Washington University in St. Louis and her BS in Pharmacy from St. Louis College of Pharmacy, where she served on the Board. She serves on the Board of ARTMS, a radioisotope technology company, as the company’s first independent director.